Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
Fig 2
Relevance between image-based response and type of CEA percentage of change over the 0th-14th day in 117 patients with advanced lung adenocarcinoma.
CEA carcinoembryonic antigen, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD-30 stable disease with tumor reduction <30%, SD+20 stable disease with tumor increasing <20%, PD progressive disease.